Mounjaro and Zepbound are two brand names for the same active ingredient, tirzepatide, made by the same manufacturer. Because the molecule is identical, the meaningful difference is not mechanism but the FDA-approved indication each label carries: Mounjaro for type 2 diabetes, Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.
Reviewed for accuracy · Last reviewed July 7, 2026The most important thing to say is that these are not different drugs. Mounjaro and Zepbound are both tirzepatide, the same GLP-1 and GIP dual agonist from the same manufacturer, so their mechanism, route, and dose range are identical.
The real difference is regulatory: the two labels carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and, separately, for obstructive sleep apnea in adults with obesity. That distinction affects how each is prescribed and covered rather than what the molecule does.
Because the active ingredient is the same, framing one as stronger than the other is not accurate. Which brand a person receives is a prescribing and coverage matter tied to the indication being treated, and that is a medical decision.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.